Published in Curr Cardiol Rev on February 01, 2013
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. Obes Res (1998) 50.73
Prevalence and trends in obesity among US adults, 1999-2008. JAMA (2010) 50.58
Positional cloning of the mouse obese gene and its human homologue. Nature (1994) 38.85
Identification and importance of brown adipose tissue in adult humans. N Engl J Med (2009) 20.57
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature (2000) 20.54
A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell (1998) 18.32
Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell (1994) 17.58
The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med (2001) 16.51
Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell (1998) 12.66
Central nervous system control of food intake and body weight. Nature (2006) 11.89
Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell (1997) 11.35
Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol (2000) 9.85
Annual deaths attributable to obesity in the United States. JAMA (1999) 8.62
Gut hormone PYY(3-36) physiologically inhibits food intake. Nature (2002) 8.30
A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes (2001) 7.54
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet (2009) 7.24
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care (2005) 7.07
Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev (2006) 6.68
Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med (2010) 6.63
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet (2008) 6.50
Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A (2001) 6.20
Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest (2002) 5.83
Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med (2003) 5.83
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care (2005) 5.77
XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care (2004) 5.34
Obesity wars: molecular progress confronts an expanding epidemic. Cell (2004) 5.29
Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A (2008) 5.21
The retardation of aging in mice by dietary restriction: longevity, cancer, immunity and lifetime energy intake. J Nutr (1986) 4.81
Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA (1999) 4.71
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med (2010) 4.52
Calorie restriction extends yeast life span by lowering the level of NADH. Genes Dev (2004) 4.51
Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet (2007) 4.47
Gastrointestinal regulation of food intake. J Clin Invest (2007) 4.47
Concern Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 4.41
Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med (2000) 4.33
Obesity. N Engl J Med (2002) 4.29
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (2010) 4.23
Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest (2004) 4.16
Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med (2005) 4.04
Neurogenesis in the hypothalamus of adult mice: potential role in energy balance. Science (2005) 4.01
Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature (1996) 3.99
Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature (1984) 3.64
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin (2008) 3.58
Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J Clin Invest (2000) 3.50
Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science (1996) 3.28
Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature (2006) 3.19
Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest (2005) 3.10
Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest (2000) 3.00
Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3. Nat Med (2004) 2.98
Intracellular signalling pathways activated by leptin. Biochem J (2006) 2.93
Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones. J Clin Endocrinol Metab (2002) 2.76
Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A (2008) 2.73
Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol (2003) 2.73
Mice overexpressing human uncoupling protein-3 in skeletal muscle are hyperphagic and lean. Nature (2000) 2.56
Absence of ghrelin protects against early-onset obesity. J Clin Invest (2005) 2.53
Enhanced metabolic efficiency contributes to weight regain after weight loss in obesity-prone rats. Am J Physiol Regul Integr Comp Physiol (2004) 2.44
Sirtuin functions in health and disease. Mol Endocrinol (2007) 2.38
Histaminergic transmission in the mammalian brain. Physiol Rev (1991) 2.28
Recent advances in understanding leptin signaling and leptin resistance. Am J Physiol Endocrinol Metab (2009) 2.27
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) (2010) 2.25
Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference. Proc Natl Acad Sci U S A (2004) 2.23
Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA (2003) 2.17
Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care (2007) 2.14
The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol (2003) 2.12
Acetyl-coenzyme A carboxylase: crucial metabolic enzyme and attractive target for drug discovery. Cell Mol Life Sci (2005) 2.08
Uncoupling proteins 2 and 3: potential regulators of mitochondrial energy metabolism. Diabetes (2000) 2.06
Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. J Clin Invest (2001) 2.05
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab (2006) 2.02
Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proc Natl Acad Sci U S A (2002) 2.00
A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab (2011) 1.98
SIM1 overexpression partially rescues agouti yellow and diet-induced obesity by normalizing food intake. Endocrinology (2006) 1.97
Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA (2003) 1.97
Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology (2007) 1.96
Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut (2003) 1.96
Caloric restriction and aging: studies in mice and monkeys. Toxicol Pathol (2008) 1.93
Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy. N Engl J Med (2010) 1.91
Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci (2009) 1.89
Sim1 haploinsufficiency causes hyperphagia, obesity and reduction of the paraventricular nucleus of the hypothalamus. Hum Mol Genet (2001) 1.80
Sirtuins: novel targets for metabolic disease. Curr Opin Investig Drugs (2008) 1.80
Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity. Nature (1997) 1.79
Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Natl Acad Sci U S A (2001) 1.79
The human beta 3-adrenoceptor: the search for a physiological function. Trends Pharmacol Sci (1994) 1.76
SB-334867-A: the first selective orexin-1 receptor antagonist. Br J Pharmacol (2001) 1.73
The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats. Eur J Neurosci (2000) 1.72
Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2005) 1.64
Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity. J Clin Invest (2002) 1.60
Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients. Clin Pharmacol Ther (2007) 1.58
Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes (2005) 1.52
Effect of leptin deficiency on metabolic rate in ob/ob mice. Am J Physiol (1999) 1.51
Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) (2009) 1.51
Mode of action of orlistat. Int J Obes Relat Metab Disord (1997) 1.51
Opioid peptides and the control of human ingestive behaviour. Neurosci Biobehav Rev (2002) 1.49
Expanding the scales: The multiple roles of MCH in regulating energy balance and other biological functions. Endocr Rev (2006) 1.46
Structure and function of the uncoupling protein from brown adipose tissue. Biochim Biophys Acta (1999) 1.45
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc (2003) (2009) 1.44
Novel pharmacotherapies for obesity poised to enter market. Nat Rev Drug Discov (2009) 1.44
Sim1 haploinsufficiency impairs melanocortin-mediated anorexia and activation of paraventricular nucleus neurons. Mol Endocrinol (2006) 1.44